Subacute Cerebellar Degeneration as Paraneoplastic Syndrome: Initial Symptom of Breast Cancer with HER2 Overexpression

2006 ◽  
Vol 7 (1) ◽  
pp. 79-80 ◽  
Author(s):  
M. Isabel Gallegos Sancho ◽  
M. Reboredo López ◽  
L. Calvo Martinez ◽  
R. García Campelo ◽  
M.S. López Facal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Paraneoplastic Syndrome ◽  
Cerebellar Degeneration ◽  
Her2 Overexpression ◽  
Initial Symptom ◽  
Subacute Cerebellar Degeneration

Paraneoplastic syndrome: Subacute cerebellar degeneration in Hodgkin's disease

2007 ◽  
Vol 48 (4) ◽  
pp. 819-822 ◽  
Author(s):  
Hendrik-Tobias Arkenau ◽  
Claire Gordon ◽  
Felicity Murphy ◽  
David Cunningham
Keyword(s):  
Paraneoplastic Syndrome ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Cerebellar Degeneration ◽  
Subacute Cerebellar Degeneration

Anti-Ri-associated paraneoplastic neurological syndrome: Initial symptom of breast cancer with HER2 overexpression and treatment by dual HER2 blockade

2018 ◽  
Vol 25 (6) ◽  
pp. 1526-1530 ◽  
Author(s):  
Omer Fatih Olmez ◽  
Oguzcan Kinikoglu ◽  
Nesrin Helvacı Yilmaz ◽  
Ahmet Bilici ◽  
Erdem Cubukcu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Female Patient ◽  
Paraneoplastic Neurological Syndrome ◽  
Her2 Overexpression ◽  
Initial Symptom ◽  
Her2 Positive ◽  
Neurological Syndrome ◽  
Her2 Positive Breast Cancer ◽  
First Case ◽  
Positive Breast Cancer

Paraneoplastic neurological syndrome is associated with anti-Ri antibodies, which are typically present with opsoclonus–myoclonus–ataxia. Human epidermal growth factor receptor 2 (HER2) overexpression is present in 15%–25% of breast cancer and is associated with poor prognosis. There are a few reports of paraneoplastic neurological syndrome associated with HER2-positive breast cancer in the literature, of which most are anti-Yo-associated paraneoplastic neurological syndrome. We present herein the case of a female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome. Following the diagnosis of paraneoplastic syndrome, chemotherapy with dual HER2 blockade and immunomodulating treatment including intravenous immunoglobulin and oral prednisolone were administered. Although the patient was negative for serum anti-Ri antibodies, there was partial clinical improvement and her neurological deficit persisted. To our knowledge, this is the first case report of female patient with HER2-positive breast cancer who had atypical anti-Ri antibody associated with opsoclonus–myoclonus paraneoplastic neurological syndrome and treated with dual HER2 blockade.

scholarly journals Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Allison N. Martin ◽  
Patrick M. Dillon ◽  
David E. Jones ◽  
David R. Brenin ◽  
David A. Lapides
Keyword(s):  
Breast Cancer ◽  
Paraneoplastic Syndrome ◽  
Radical Mastectomy ◽  
Cerebellar Degeneration ◽  
Paraneoplastic Syndromes ◽  
Paraneoplastic Cerebellar Degeneration ◽  
Modified Radical Mastectomy ◽  
Stage Iiia ◽  
Pseudobulbar Affect ◽  
New Onset

Paraneoplastic cerebellar degeneration (PCD) is a rare anti-Yo mediated paraneoplastic syndromes rarely that is infrequently associated with breast cancer. We present a case of a 52-year-old female presenting with diplopia, gait instability, dysarthria, dysphagia, nystagmus, and, most notably, new onset paroxysmal episodes of uncontrollable crying concerning for pseudobulbar affect (PBA). Serologic testing showed anti-Yo antibodies. The patient was found to have stage IIIA breast cancer as the inciting cause of the paraneoplastic syndrome. The patient was treated with neoadjuvant chemotherapy, modified radical mastectomy, adjuvant Herceptin, and pertuzumab. She was given IVIG for paraneoplastic syndrome, antidepressants, and dextromethorphan-quinidine (Nuedexta), the first FDA-approved therapy for PBA. With multimodality therapy, she demonstrated significant improvement in neurologic and mood symptoms associated with PCD and PBA.

scholarly journals Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis

2019 ◽  
Vol Volume 11 ◽  
pp. 8043-8054 ◽  
Author(s):  
Lin He ◽  
Qian Wu ◽  
Jing Xiong ◽  
Zhumin Su ◽  
Biyuan Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Her2 Overexpression ◽  
Breast Cancer Patients

Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer

2010 ◽  
Vol 258 (5) ◽  
pp. 921-922 ◽  
Author(s):  
Domenico Plantone ◽  
Pietro Caliandro ◽  
Raffaele Iorio ◽  
Giovanni Frisullo ◽  
Viviana Nociti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Spinal Cord ◽  
Paraneoplastic Syndrome ◽  
Spinal Cord Involvement

scholarly journals Current Approaches and Emerging Directions in HER2-resistant Breast Cancer

2014 ◽  
Vol 8 ◽  
pp. BCBCR.S9453 ◽  
Author(s):  
Adam M. Brufsky
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Molecular Mechanisms ◽  
Mammalian Target Of Rapamycin ◽  
Growth Factor Receptor ◽  
Initial Response ◽  
Her2 Overexpression ◽  
Breast Cancers ◽  
Intrinsic Resistance ◽  
Her2 Positive

Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response. Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors. Numerous clinical trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer. This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer.

scholarly journals Nanolipoprotein mediated Her2 protein transfection induces malignant transformation in human breast acinar cultures

2020 ◽  
Author(s):  
Wei He ◽  
Angela C. Evans ◽  
Matthew Coleman ◽  
Claire Robertson
Keyword(s):  
Breast Cancer ◽  
Malignant Transformation ◽  
Cell Surface Receptor ◽  
Cell Phenotype ◽  
Her2 Overexpression ◽  
Malignant Cells ◽  
Transformation Techniques ◽  
Her2 Protein ◽  
Surface Receptor ◽  
Protein Transfection

AbstractHer2 overexpression is associated with an aggressive form of breast cancer and malignant transformation. We sought to determine if a nano-carrier system could introduce Her2 protein to non-malignant cells and determine the effects on cell phenotype and transcriptome. With stimulation with Her2-NLPs, we observed uptake of Her2 protein and a decreased probability of individual non-malignant cells forming polar growth arrested acinar-like structures. The NLP delivery system alone or Her2-NLPs plus trastuzumab showed no effect on acinar organization rate. Transcriptomics revealed essentially no effect of empty NLPs versus untreated cells whereas Her2-NLPs versus either untreated or empty NLP treated cells revealed upregulation of several factors associated with breast cancer. Pathway analysis also suggested that known nodes downstream of Her2 were activated in response to Her2-NLP treatment. This suggests that Her2-NLPs are sufficient for malignant transformation of non-malignant cells and that this system offers a new model for studying cell surface receptor signaling without genomic modification or transformation techniques.

scholarly journals Is There Any Rationale for Detecting Hormone Receptor/HER2 Status with Rebiopsy Without Progression Upfront Metastatic Breast Cancer? with 2 Cases

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Duman BB ◽  
Cil T
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Maintenance Therapy ◽  
Hormone Receptor ◽  
Tumor Heterogeneity ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Neoadjuvant Treatment ◽  
Metastatic Breast ◽  
Her2 Overexpression

Alteration of biomarkers is well-documented in breast cancer at locoregional recurrence or metastasis attributed to tumor heterogeneity and change in biology. There is some data about discordance between primary and metastatic sites. At the same time hormone, receptor status can change after neoadjuvant treatment and at the time of recurrence. Metastatic breast cancer without progression or recurrence after the targeted chemotherapy combination for planning maintenance therapy in Human epidermal growth factor receptor 2 (HER2) overexpression positive hormone receptors positive or triple-negative patient after chemotherapy. In guidelines, the time of rebiopsy has no exact time, if the time of biopsy is usually after the progression of the tumor. We presented cases in which we detected different hormone receptor statuses from the beginning without progression and before deciding on maintenance therapy. This subject is important for deciding therapy in the aspect of heterogeneous tumors like breast cancer. The important decision of rebiopsy time is debate. In this aspect, these two cases are important examples for these kinds of patients tumor heterogeneity in breast cancer is one of the most widely known entities. We found that two patients, one of whom was estrogen progesterone receptor negative HER2 3 (+++) at the time of diagnosis and the other who was triple negative at the time of diagnosis, had positive hormone receptors in the re-biopsies without progression. We aimed to discuss the tumor heterogeneity and timing of rebiopsy in breast cancer in the light of two cases.

scholarly journals Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study

PLoS ONE ◽  
2022 ◽  
Vol 17 (1) ◽  
pp. e0262468
Author(s):  
Susanna Hilda Hutajulu ◽  
Yayi Suryo Prabandari ◽  
Bagas Suryo Bintoro ◽  
Juan Adrian Wiranata ◽  
Mentari Widiastuti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Educational Interventions ◽  
Disease Stage ◽  
Future Research ◽  
Multivariable Logistic Regression Analysis ◽  
Initial Symptom ◽  
Diagnosis Delay ◽  
Cancer Stage ◽  
Breast Cancer Patients ◽  
Cross Sectional

Purpose To investigate factors associated with delays in presentation and diagnosis of women with confirmed breast cancer (BC). Methods A cross-sectional study nested in an ongoing prospective cohort study of breast cancer patients at Dr Sardjito Hospital, Yogyakarta, Indonesia, was employed. Participants (n = 150) from the main study were recruited, with secondary information on demographic, clinical, and tumor variables collected from the study database. A questionnaire was used to gather data on other socioeconomic variables, herbal consumption, number of healthcare visits, knowledge-attitude-practice of BC, and open-ended questions relating to initial presentation. Presentation delay (time between initial symptom and first consultation) was defined as ≥3 months. Diagnosis delay was defined as ≥1 month between presentation and diagnosis confirmation. Impact on disease stage and determinants of both delays were examined. A Kruskal-Wallis test was used to assess the length and distribution of delays by disease stage. A multivariable logistic regression analysis was conducted to explore the association between delays, cancer stage and factors. Results Sixty-five (43.3%) patients had a ≥3-month presentation delay and 97 (64.7%) had a diagnosis confirmation by ≥1 month. Both presentation and diagnosis delays increased the risk of being diagnosed with cancer stage III-IV (odds ratio/OR 2.21, 95% CI 0.97–5.01, p = 0.059 and OR 3.03, 95% CI 1.28–7.19, p = 0.012). Visit to providers ≤3 times was significantly attributed to a reduced diagnosis delay (OR 0.15, 95% CI 0.06–0.37, p <0.001), while having a family history of cancer was significantly associated with increased diagnosis delay (OR 2.28, 95% CI 1.03–5.04, p = 0.042). The most frequent reasons for delaying presentation were lack of awareness of the cause of symptoms (41.5%), low perceived severity (27.7%) and fear of surgery intervention (26.2%). Conclusions Almost half of BC patients in our setting had a delay in presentation and 64.7% experienced a delay in diagnosis. These delays increased the likelihood of presentation with a more advanced stage of disease. Future research is required in Indonesia to explore the feasibility of evidence-based approaches to reducing delays at both levels, including educational interventions to increase awareness of BC symptoms and reducing existing complex and convoluted referral pathways for patients suspected of having cancer.

Sign in / Sign up

Export Citation Format

Share Document